May 27, 2026

Biohub unveils AI world model for drug discovery, enhancing protein design

Mark Zuckerberg’s philanthropic venture, Biohub, has launched a new AI world model aimed at accelerating drug discovery by enhancing the understanding of protein biology. Developed with insights from evolutionary scale modeling, this open-source model is designed to assist scientists in creating stable and effective proteins, which has been a persistent challenge in the field. The model’s efficacy has been verified in lab tests targeting cancer and immune conditions, where it successfully designed new protein binders that reactivate immune cells. Since its founding in 2015, Biohub has integrated advanced AI capabilities, previously through the acquisition of the AI-biology startup EvolutionaryScale, and aims to bolster research efficiency in the pharmaceutical industry, which is increasingly turning to automated systems for drug development.

Meta: Meta is a technology company that develops social media platforms, metaverse technologies, and AI systems under the leadership of CEO Mark Zuckerberg. Zuckerberg’s role at Meta is referenced in the context of his separate philanthropic activities through Biohub, which operates independently to focus on biomedical research.
Biohub: Biohub is the biomedical research arm of the Chan Zuckerberg Initiative focused on advancing scientific understanding of human biology through technology and collaboration. In this news, Biohub launched an open-source AI world model based on evolutionary scale modeling to help researchers design new proteins for drug discovery in areas like cancer and immune diseases. The organization is also providing access via its own platform and partners to support broader adoption by scientists.
SandboxAQ: SandboxAQ is a technology company providing AI and quantum solutions for scientific and enterprise applications, including biology platforms. Biohub has partnered to make its AI world models accessible through SandboxAQ to facilitate use in protein research and related fields.
Alex Rives: Alex Rives serves as head of science at Biohub, overseeing AI-driven biology initiatives including the development of protein modeling tools. In the news, he discussed the open-source release of the models, their integration on external platforms, and plans to provide compute credits to enable researchers to apply them in their work.
Priscilla Chan: Priscilla Chan is a physician and co-founder of the Chan Zuckerberg Initiative, where she directs biomedical research priorities including the unification of efforts under Biohub. She is directly involved in the launch of the new AI world model, highlighting its validation in immune diseases and cancer and expressing optimism about its adoption by other researchers.
Mark Zuckerberg: Mark Zuckerberg is the founder and CEO of Meta, with a long-standing commitment to philanthropy alongside his wife. Through Biohub, he is supporting the development and release of advanced AI tools for protein biology and drug discovery as part of efforts to accelerate scientific progress in health.
AWS Bio Discovery: AWS Bio Discovery is a cloud platform offered by Amazon Web Services that supports biological research and discovery workflows. It is one of the platforms where Biohub’s new AI protein models will be made available to expand access for scientists working on drug design.

`json
{
“Accessibility”: “The open-source models are being distributed through multiple platforms, including a dedicated Biohub service that allows scientists to run them on Biohub’s servers with provided compute resources.”,
“Industry Trend”: “Pharmaceutical firms are increasingly turning to AI tools and automated systems to improve efficiency in research and development for drug discovery.”,
“Model Application”: “Researchers have used the AI models to design new protein binders that reactivate immune cells in laboratory tests targeting cancer and immune conditions.”
}
`

AI tools built by Emerald Force

Built and supported by Emerald Force.

You might also like